June 30, 2020 / 7:15 PM / 4 days ago

BRIEF-Ultragenyx Announces U.S. FDA Approval Of Dojolvi(Ux007/Triheptanoin) For The Treatment Of Long-Chain Fatty Acid Oxidation Disorders

June 30 (Reuters) - Ultragenyx Pharmaceutical Inc:

* ULTRAGENYX ANNOUNCES U.S. FDA APPROVAL OF DOJOLVI™ (UX007/TRIHEPTANOIN), THE FIRST FDA-APPROVED THERAPY FOR THE TREATMENT OF LONG-CHAIN FATTY ACID OXIDATION DISORDERS

* ULTRAGENYX PHARMACEUTICAL - EXPECTS DOJOLVI TO BE AVAILABLE TO PATIENTS IN NEXT 30 DAYS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below